首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1743285

全球甲狀腺疾病：診斷與治療市場

Global Thyroid Gland Disorders: Diagnostics and Treatment Market

出版日期: 2025年05月30日 | 出版商:

BCC Research | 英文 175 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

全球甲狀腺疾病診斷和治療市場規模預計將從2024年的155億美元和2025年的163億美元成長到2030年的210億美元，預測期內（2025-2030年）的年複合成長率為 5.2%。

預計北美市場規模將從2024年的66億美元和2025年的69億美元增加至2030年的91億美元，2025-2030年預測期間的年複合成長率為5.5%。預計亞太市場規模將從2024年的30億美元和2025年的32億美元增加到2030年的44億美元，年複合成長率為6.4%。

本報告調查了全球甲狀腺疾病診斷和治療市場，並提供了全面的市場概述、市場影響因素和市場機會的分析、法律制度、新興技術和技術發展的趨勢、市場規模的趨勢和預測、各個細分市場和地區的詳細分析、競爭格局以及主要企業的概況。

市場促進因素
甲狀腺癌發生率上升
甲狀腺疾病盛行率不斷上升
提高對甲狀腺疾病的認知和政策舉措
個人化醫療治療甲狀腺疾病
市場限制
治療的副作用
低收入地區的交通受限
市場機會
人工智慧簡介
先進治療學
市場挑戰
醫療保健差距和資金籌措挑戰
終身服藥的必要性

第4章監管情況

核准流程：美國
核准程序：歐盟
核准流程：亞太地區
藥品核准與監管
左甲狀腺素治療
抗甲狀腺藥物
生物製藥和生物相似藥的監管
醫療設備和診斷法規
就地檢驗和臨床檢測
穿戴式裝置和數位健康解決方案
未來趨勢和監管變化

第5章新興技術與發展

概述
甲狀腺疾病診斷新技術
混合特徵選擇與深度學習框架
甲狀腺和副甲狀腺手術的螢光技術
再生醫學與生物工程
生物穿戴技術
行動應用程式
近期藥品和醫療設備的核准和上市
專利分析
調查結果

第6章市場區隔分析

細分市場
關鍵要點
市場分析：依疾病
甲狀腺機能低下症
甲狀腺功能亢進
甲狀腺癌
其他
市場分析：依類型
摘要
診斷
治療
市場分析：依最終用戶
摘要
醫院和專科診所
零售及網路藥局
研究和學術機構
居家照護
地理分佈
市場分析：依地區
摘要
北美洲
歐洲
亞太地區
南美洲
中東和非洲

第7章競爭訊息

摘要
主要企業市場佔有率
發展與策略
協議、合作與夥伴關係
獲得

第8章甲狀腺疾病診斷與治療產業的永續性：ESG 視角

ESG：簡介
主要企業的舉措
ESG風險評估
BCC 的觀點

第9章附錄

調查方法
來源
簡稱
公司簡介
ABBOTT
ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
FRESENIUS SE & CO. KGAA
GSK PLC.
LILLY
MERCK KGAA
NOVARTIS AG
PFIZER INC.
SANOFI
SIEMENS HEALTHINEERS AG
TERUMO CORP.
新興Start-Ups/市場顛覆者

簡介目錄圖表

Product Code: HLC303A

The global market for diagnostics and treatment of thyroid gland disorders was valued at $15.5 billion in 2024 and is estimated to increase from $16.3 billion in 2025 to reach $21.0 billion by 2030, at a compound annual growth rate (CAGR) of 5.2% from 2025 through 2030.

The North American market for diagnostics and treatment of thyroid gland disorders was valued at $6.6 billion in 2024 and is estimated to increase from $6.9 billion in 2025 to reach $9.1 billion by 2030, at a CAGR of 5.5% from 2025 through 2030.

The Asia-Pacific market for diagnostics and treatment of thyroid gland disorders was valued at $3.0 billion in 2024 and is estimated to increase from $3.2 billion in 2025 to reach $4.4 billion by 2030, at a CAGR of 6.4% from 2025 through 2030.

Report Scope

The report analyzes trends in the global market for diagnostics and treatment of thyroid gland disorders. The report includes global revenue ($ million) for the base year 2024, estimated data for 2025, and for the forecast period of 2026 through 2030. The market is segmented by type of disease, product type, end user and region. The disease types are segmented into hypothyroidism, hyperthyroidism, thyroid cancer, and others. Product types are diagnostics and treatments. The diagnostics market is segmented into diagnostic, blood and imaging tests. The treatment market is segmented into medication, thyroid surgery, thyroid eye disease (TED) treatment and other end users are hospitals, specialty clinics, retail and online pharmacies, research and academic institutions, and patient and home care settings. The regions covered are North America, Europe, Asia-Pacific, and the Rest of the World (RoW. North American consists of the U.S., Canada, and Mexico. Europe includes Germany, the U.K., Italy, France, Spain and the Rest of Europe. Asia-Pacific includes China, Japan, India, South Korea and the Rest of Asia-Pacific.

This report focuses on trends and challenges that affect the market, including emerging technologies. It includes an analysis of the competitive landscape, with the rankings and market shares of the leading companies in the global market. The report has a chapter on environmental, social, and corporate governance (ESG) developments and includes company profiles that covers key financials, product portfolios and recent news.

Report Includes

97 data tables and 62 additional tables
An overview of the current and future global markets for thyroid gland disorder
An analysis of the global market trends with market revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030
Estimates of the size and revenue prospects of the global market, along with a market share analysis by type, disease type, end-user industry, and region
Facts and figures pertaining to market dynamics, technological advances, regulations, and the impact of macroeconomic factors
Analysis of market opportunities from a Porter's Five Forces perspective, and a value chain analysis considering the prevailing micro- and macro environmental factors
Coverage of advances in thyroid cancer diagnosis such as genomic tests and treatments, as well as the side effects of current treatments such as radioactive iodine
Evaluation of ESG practices in the industry, consumer attitudes towards sustainability, risks and opportunity assessment, ratings and matrices
A patent analysis with emphasis on emerging technologies and new developments in the market
Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
Company profiles of major players within the industry, including Amgen Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, Bristol-Myers Squibb Co., and Pfizer Inc.

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary

Chapter 2 Market Overview

Overview
Conventional and Novel Technologies
Diagnostics in Thyroid Gland Disorders
Treatment of Thyroid Gland Disorders
Porter's Five Forces Analysis
Potential for New Entrants (Moderate)
Bargaining Power of Suppliers (Moderate to High)
Bargaining Power of Buyers (Moderate to High)
Threat of Substitutes (Low to Moderate)
Industry Competitiveness (High)
Macroeconomic Factors
Aging Population
Regulatory Environment
Growing Incidence of Cancer
Government Policy and Collaboration

Chapter 3 Market Dynamics

Market Drivers
Growing Prevalence of Thyroid Cancer
Growing Prevalence of Thyroid Disorders
Rising Awareness and Policy Initiatives for Thyroid Disorders
Managing Thyroid Disorders through Personalized Medicine
Market Restraints
Side Effects of Treatment
Limited Access in Low-Income Regions
Market Opportunities
Incorporation of AI
Advanced Therapeutics
Market Challenges
Healthcare Disparities and Funding Challenges
Requirement for Lifelong Medication

Chapter 4 Regulatory Landscape

U.S. Approval Process
EU Approval Process
Asia-Pacific Approval Process
Drug Approval and Regulations
Levothyroxine-Based Treatments
Anti-Thyroid Medications
Biologic and Biosimilar Regulations
Medical Devices and Diagnostics Regulations
Point-of-Care and Laboratory Tests
Wearable and Digital Health Solutions
Future Trends and Regulatory Changes

Chapter 5 Emerging Technologies and Developments

Overview
Emerging Technologies in Thyroid Disorder Diagnostics
Hybrid Feature Selection and Deep Learning Framework
Autofluorescence Technology for Thyroid and Parathyroid Surgery
Regenerative Medicine and Bioengineering
Biowearable Technology
Mobile Apps
Recent Approvals and Launches of Drug and Device Products
Patent Analysis
Findings

Chapter 6 Market Segmentation Analysis

Segmentation Breakdown
Key Takeaways
Market Analysis by Disease Type
Hypothyroidism
Hyperthyroidism
Thyroid Cancer
Other Diseases
Market Analysis by Type
Takeaways
Diagnostics
Treatment
Market Analysis by End User
Takeaways
Treatment in Hospitals and Specialty Clinics
Retail and Online Pharmacies
Research and Academic Institutes
Home Care Settings
Geographic Breakdown
Market Analysis by Region
Takeaways
North America
Europe
Asia-Pacific
South America
Middle East and Africa

Chapter 7 Competitive Intelligence

Takeaways
Market Shares of Leading Companies
Developments and Strategies
Agreements, Collaborations and Partnerships
Acquisitions

Chapter 8 Sustainability in the Diagnostics and Treatment of Thyroid Gland Disorders Industry: ESG Perspective

Introduction to ESG
Initiatives by Leading Companies
ESG Risk Ratings
BCC Research Viewpoint

Chapter 9 Appendix

Research Methodology
Sources
Abbreviations
Company Profiles
ABBOTT
ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
FRESENIUS SE & CO. KGAA
GSK PLC.
LILLY
MERCK KGAA
NOVARTIS AG
PFIZER INC.
SANOFI
SIEMENS HEALTHINEERS AG
TERUMO CORP.
Emerging Start-ups/ Market Disruptors

簡介目錄圖表

List of Tables

Summary Table : Global Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Region, Through 2030
Table 1 : Incidence of Thyroid Cancer in 2022
Table 2 : Hypothyroidism Prevalence in the U.S. based on Optum Administrative Claims Database, 2012-2019
Table 3 : Guidelines on Diagnosis and Management of Genetic Disorders of Thyroid Hormone, European Thyroid Association, 2024
Table 4 : Comparative of HFSDLF Framework and Other Approaches, 2025
Table 5 : Published Patents on Thyroid Gland Disorders: Diagnostics and Treatment, January 2024-January 2025
Table 6 : Global Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 7 : Global Market for Diagnostics and Treatment of Hypothyroidism, by Region, Through 2030
Table 8 : Global Market for Diagnostics and Treatment of Hyperthyroidism, by Region, Through 2030
Table 9 : FDA-Approved Drugs in Advanced RR-DTC, 2025
Table 10 : Tyrosine Kinase Inhibitors Tested in Thyroid Cancers, 2025
Table 11 : Global Market for Diagnostics and Treatment of Thyroid Cancer, by Region, Through 2030
Table 12 : Global Market for Diagnostics and Treatment of Other Thyroid Gland Disorders, by Region, Through 2030
Table 13 : Global Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 14 : Global Market for Diagnostics of Thyroid Gland Disorders, by Region, Through 2030
Table 15 : Global Market for Diagnostics of Thyroid Gland Disorders, by Type, Through 2030
Table 16 : Global Market for Blood Test Diagnostics of Thyroid Gland Disorders, by Region, Through 2030
Table 17 : Global Market for Imaging Diagnostic Tests of Thyroid Gland Disorders, by Region, Through 2030
Table 18 : Global Market for Treatment of Thyroid Gland Disorders, by Region, Through 2030
Table 19 : Global Market for Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 20 : Global Market for Medication Treatment of Thyroid Gland Disorders, by Region, Through 2030
Table 21 : Global Market for Thyroid Surgery, by Region, Through 2030
Table 22 : Biologics in the Pipeline for Potential Use in the Treatment of TED, 2025
Table 23 : Global Market for the Treatment of TED, by Region, Through 2030
Table 24 : Global Market for RAI Treatment of Thyroid Gland Disorders, by Region, Through 2030
Table 25 : Global Market for Other Treatments of Thyroid Gland Disorders, by Region, Through 2030
Table 26 : Global Market for Diagnostics and Treatment of Thyroid Gland Disorders, by End User, Through 2030
Table 27 : Global Market for Diagnostics and Treatment of Thyroid Gland Disorders in Hospitals and Specialty Clinics, by Region, Through 2030
Table 28 : Global Market for Diagnostics and Treatment of Thyroid Gland Disorders in Retail and Online Pharmacies, by Region, Through 2030
Table 29 : Global Market for Diagnostics and Treatment of Thyroid Gland Disorders in Research and Academic Institutes, by Region, Through 2030
Table 30 : Global Market for Diagnostics and Treatment of Thyroid Gland Disorders in Home Care Settings, by Region, Through 2030
Table 31 : Global Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Region, Through 2030
Table 32 : North American Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 33 : North American Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 34 : North American Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Diagnostics, Through 2030
Table 35 : North American Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Treatment, Through 2030
Table 36 : North American Market for Diagnostics and Treatment of Thyroid Gland Disorders, by End User, Through 2030
Table 37 : North American Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Country, Through 2030
Table 38 : U.S. Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 39 : U.S. Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 40 : Canadian Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 41 : Canadian Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 42 : Mexican Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 43 : Mexican Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 44 : Demographic Patterns in Thyroid Medication Use per 10,000 Population in European Countries, 2022
Table 45 : European Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 46 : European Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 47 : European Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Diagnostics, Through 2030
Table 48 : European Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Treatment, Through 2030
Table 49 : European Market for Diagnostics and Treatment of Thyroid Gland Disorders, by End User, Through 2030
Table 50 : European Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Country, Through 2030
Table 51 : U.K. Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 52 : U.K. Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 53 : French Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 54 : French Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 55 : Italian Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 56 : Italian Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 57 : German Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 58 : German Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 59 : Spanish Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 60 : Spanish Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 61 : Rest of European Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 62 : Rest of European Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 63 : Asia-Pacific Market for Diagnostics and Treatment of Thyroid Gland Disorder, by Disease, Through 2030
Table 64 : Asia-Pacific Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 65 : Asia-Pacific Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Diagnostics, Through 2030
Table 66 : Asia-Pacific Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Treatment, Through 2030
Table 67 : Asia-Pacific Market for Diagnostics and Treatment of Thyroid Gland Disorders, by End User, Through 2030
Table 68 : Asia-Pacific Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Country, Through 2030
Table 69 : Chinese Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease Type, Through 2030
Table 70 : Chinese Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 71 : Indian Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 72 : Indian Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 73 : Japanese Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 74 : Japanese Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 75 : Australian Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 76 : Australian Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 77 : South Korean Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 78 : South Korean Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 79 : Rest of Asia-Pacific Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 80 : Rest of Asia-Pacific Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 81 : South American Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 82 : South American Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 83 : South American Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Diagnostics, Through 2030
Table 84 : South American Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Treatment, Through 2030
Table 85 : South American Market for Diagnostics and Treatment of Thyroid Gland Disorders, by End User, Through 2030
Table 86 : MEA Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 87 : MEA Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 88 : MEA Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Diagnostics, Through 2030
Table 89 : MEA Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Treatment, Through 2030
Table 90 : MEA Market for Diagnostics and Treatment of Thyroid Gland Disorders, by End User, Through 2030
Table 91 : Leading Companies in the Market, 2024
Table 92 : Agreements, Collaborations and Partnerships in the Diagnostics and Treatment of Thyroid Gland Disorder Industry, 2021-2025
Table 93 : Acquisitions in the Diagnostics and Treatment for Thyroid Gland Disorder Industry, 2023-2024
Table 94 : ESG Highlights, by Leading Companies, 2023 and 2024
Table 95 : ESG Risk Rankings, 2024
Table 96 : Report Information Sources
Table 97 : Abbreviations Used in this Report
Table 98 : Abbott: Company Snapshot
Table 99 : Abbott: Financial Performance, FY 2023 and 2024
Table 100 : Abbott: Product Portfolio
Table 101 : Abbott: News/Key Developments 2023-2025
Table 102 : AbbVie Inc.: Company Snapshot
Table 103 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
Table 104 : AbbVie Inc.: Product Portfolio
Table 105 : AbbVie Inc.: News/Key Developments, 2023 and 2024
Table 106 : Amgen Inc.: Company Snapshot
Table 107 : Amgen Inc.: Financial Performance, FY 2023 and 2024
Table 108 : Amgen Inc.: Product Portfolio
Table 109 : Amgen Inc.: News/Key Developments, 2021-2024
Table 110 : AstraZeneca: Company Snapshot
Table 111 : AstraZeneca: Financial Performance, FY 2023 and 2024
Table 112 : AstraZeneca: Product Portfolio
Table 113 : AstraZeneca: News/Key Developments, 2021-2024
Table 114 : Bristol-Myers Squibb Co.: Company Snapshot
Table 115 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
Table 116 : Bristol-Myers Squibb Co.: Product Portfolio
Table 117 : Bristol-Myers Squibb Co.: News/Key Developments, 2023-2025
Table 118 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 119 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 120 : F. Hoffmann-La Roche Ltd. : Product Portfolio
Table 121 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022-2025
Table 122 : Fresenius SE & Co. KGaA: Company Snapshot
Table 123 : Fresenius SE & Co. KGaA: Financial Performance, FY 2023 and 2024
Table 124 : Fresenius SE & Co. KGaA: Product Portfolio
Table 125 : Fresenius SE & Co. KGaA: News/Key Developments, 2023 and 2024
Table 126 : GSK plc.: Company Snapshot
Table 127 : GSK plc.: Financial Performance, FY 2023 and 2024
Table 128 : GSK plc.: Product Portfolio
Table 129 : GSK plc.: News/Key Developments, 2021-2024
Table 130 : Lilly: Company Snapshot
Table 131 : Lilly: Financial Performance, FY 2023 and 2024
Table 132 : Lilly: Product Portfolio
Table 133 : Lilly: News/Key Developments, 2023 and 2024
Table 134 : Merck KGaA.: Company Snapshot
Table 135 : Merck KGaA.: Financial Performance, FY 2023 and 2024
Table 136 : Merck KGaA: Product Portfolio
Table 137 : Merck KGaA.: News/Key Developments, 2021-2023
Table 138 : Novartis AG: Company Snapshot
Table 139 : Novartis AG: Financial Performance, FY 2023 and 2024
Table 140 : Novartis AG: Product Portfolio
Table 141 : Novartis AG: News/Key Developments, 2022-2024
Table 142 : Pfizer Inc.: Company Snapshot
Table 143 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
Table 144 : Pfizer Inc.: Product Portfolio
Table 145 : Pfizer Inc.: News/Key Developments, 2022-2024
Table 146 : Sanofi: Company Snapshot
Table 147 : Sanofi: Financial Performance, FY 2023 and 2024
Table 148 : Sanofi: Product Portfolio
Table 149 : Sanofi: News/Key Developments, 2022 and 2023
Table 150 : Siemens Healthineers AG: Company Snapshot
Table 151 : Siemens Healthineers AG: Financial Performance, FY 2023 and 2024
Table 152 : Siemens Healthineers AG: Product Portfolio
Table 153 : Siemens Healthineers AG: News/Key Developments, 2024
Table 154 : Terumo Corp.: Company Snapshot
Table 155 : Terumo Corp.: Financial Performance, FY 2022 and 2023
Table 156 : Terumo Corp.: Product Portfolio
Table 157 : Terumo Corp.: News/Key Developments, 2023
Table 158 : Emerging Startups

List of Figures

Summary Figure : Shares of Global Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Region, 2024
Figure 1 : Existing and Emerging Technologies for the Treatment of Thyroid Disorders
Figure 2 : Porter's Five Forces Market Analysis
Figure 3 : Market Dynamics of Thyroid Gland Disorders
Figure 4 : Shares of Global Thyroid Cancer Mortality in Males, by Region, 2022
Figure 5 : Thyroid Health Awareness in the Saudi Population: A Community Study
Figure 6 : Shares of Global Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, 2024
Figure 7 : Shares of Global Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, 2024
Figure 8 : Shares of Global Market for Diagnostics of Thyroid Gland Disorders, by Type, 2024
Figure 9 : Shares of Global Market for Treatment of Thyroid Gland Disorders by Type, 2024
Figure 10 : Shares of Global Market for Diagnostics and Treatment of Thyroid Gland Disorders, by End User, 2024
Figure 11 : Shares of Global Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Region, 2024
Figure 12 : North American Market Shares for Diagnostics and Treatment of Thyroid Gland Disorder, by Country, 2024
Figure 13 : European Market Shares for Diagnostics and Treatment of Thyroid Gland Disorders, by Country, 2024
Figure 14 : Asia-Pacific Market Shares for Diagnostics and Treatment of Thyroid Gland Disorders, by Country, 2024
Figure 15 : Shares for Companies in the Market for Diagnostics and Treatment of Thyroid Gland Disorders, 2024
Figure 16 : Abbott: Revenue Share, by Business Unit, FY 2024
Figure 17 : Abbott: Revenue Share, by Country/Region, FY 2024
Figure 18 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2024
Figure 19 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2024
Figure 20 : Amgen Inc.: Revenue Share, by Drug, FY 2024
Figure 21 : Amgen Inc.: Revenue Share, by Country/Region, FY 2024
Figure 22 : AstraZeneca: Revenue Share, by Business Unit, FY 2024
Figure 23 : AstraZeneca: Revenue Share, by Region/Country, FY 2024
Figure 24 : Bristol-Myers Squibb Co.: Revenue Share, by Business Unit, FY 2024
Figure 25 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2024
Figure 26 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
Figure 27 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2024
Figure 28 : Fresenius SE & Co. KGaA: Revenue Share, by Business Unit, FY 2024
Figure 29 : Fresenius SE & Co. KGaA: Revenue Share, by Country/Region, FY 2024
Figure 30 : GSK plc.: Revenue Share, by Business Unit, FY 2024
Figure 31 : GSK plc.: Revenue Share, by Country/Region, FY 2024
Figure 32 : Lilly: Revenue Share, by Business Unit, FY 2024
Figure 33 : Lilly: Revenue Share, by Country/Region, FY 2024
Figure 34 : Merck KGaA: Revenue Share, by Business Unit, FY 2024
Figure 35 : Merck KGaA.: Revenue Share, by Country/Region, FY 2024
Figure 36 : Novartis AG: Revenue Share, by Business Unit, FY 2024
Figure 37 : Novartis AG: Revenue Share, by Country/Region, FY 2024
Figure 38 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2024
Figure 39 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2024
Figure 40 : Sanofi: Revenue Share, by Business Unit, FY 2024
Figure 41 : Sanofi: Revenue Share, by Country/Region, FY 2024
Figure 42 : Siemens Healthineers AG: Revenue Share, by Business Unit, FY 2024
Figure 43 : Siemens Healthineers AG: Revenue Share, by Country/Region, FY 2024
Figure 44 : Terumo Corp.: Revenue Share, by Business Unit, FY 2023
Figure 45 : Terumo Corp.: Revenue Share, by Country/Region, FY 2023